Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?

Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?

Hepatocellular carcinoma (HCC) and biliary tract cancers (BTC) exhibit a poor prognosis with 5-year overall survival rates around 15%, all stages combined. Most of these primary liver malignancies are metastatic at diagnostic, with only limited therapeutic options, relying mainly on systemic therapi...

Full description

Bibliographic Details
Main Authors:	Alice Boilève, Marc Hilmi, Matthieu Delaye, Annemilaï Tijeras-Raballand, Cindy Neuzillet
Format:	Article
Language:	English
Published:	MDPI AG 2021-05-01
Series:	Cancers
Subjects:	hepatocellular carcinoma biliary tract cancers cholangiocarcinoma immune checkpoint inhibitor targeted therapy biomarker
Online Access:	https://www.mdpi.com/2072-6694/13/11/2708

Similar Items

Immunotherapy in Advanced Biliary Tract Cancers
by: Alice Boilève, et al.
Published: (2021-03-01)

Immune Therapy for Liver Cancers
by: Marc Hilmi, et al.
Published: (2019-12-01)

Locoregional Treatments in Cholangiocarcinoma and Combined Hepatocellular Cholangiocarcinoma
by: Matteo Renzulli, et al.
Published: (2021-07-01)

The State of Immunotherapy in Hepatobiliary Cancers
by: Farhan Z. Ilyas, et al.
Published: (2021-08-01)

HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis
by: Thomas Albrecht, et al.
Published: (2019-12-01)

Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures
by: Alessandro Rizzo, et al.
Published: (2020-11-01)

Promising Molecular Targets for the Targeted Therapy of Biliary Tract Cancers: An Overview
by: Yang W, et al.
Published: (2021-02-01)

Biliary Paracoccidioidomycosis: An Unusual Infection Simulating Malignant Neoplasm
by: Klaus Steinbrück, et al.
Published: (2019-01-01)

Unravelling the Diagnostic Dilemma: A MicroRNA Panel of Circulating MiR-16 and MiR-877 as A Diagnostic Classifier for Distal Bile Duct Tumors
by: Laura L. Meijer, et al.
Published: (2019-08-01)

Current Progress and Future Perspectives of Immune Checkpoint Inhibitors in Biliary Tract Cancer
by: Seesaha PK, et al.
Published: (2021-03-01)

Alkaline phosphatase normalization is a biomarker of improved survival in primary sclerosing cholangitis
by: Moira Hilscher, et al.
Published: (2016-03-01)

Rare DNA Mismatch Repair-Related Protein Loss in Patients with Intrahepatic Cholangiocarcinoma and Combined Hepatocellular-Cholangiocarcinoma and Their Response to Immunotherapy
by: Yu J, et al.
Published: (2021-05-01)

Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma: A Literature Review and Treatment Perspectives
by: Daniel M. Girardi, et al.
Published: (2021-12-01)

Levels of Circulating PD-L1 Are Decreased in Patients with Resectable Cholangiocarcinoma
by: Christoph Roderburg, et al.
Published: (2021-06-01)

Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm
by: Sakti Chakrabarti, et al.
Published: (2020-07-01)

Molecular Profiling in Daily Clinical Practice: Practicalities in Advanced Cholangiocarcinoma and Other Biliary Tract Cancers
by: Angela Lamarca, et al.
Published: (2020-09-01)

Tumor Infiltrating Neutrophils Are Frequently Found in Adenocarcinomas of the Biliary Tract and Their Precursor Lesions with Possible Impact on Prognosis
by: Vittorio Branchi, et al.
Published: (2021-03-01)

Significance of serum ferritin as a prognostic factor in advanced hepatobiliary cancer patients treated with Korean medicine: a retrospective cohort study
by: Anna Song, et al.
Published: (2018-06-01)

Intraductal papillary mucinous neoplasm of biliary ducts: Literature review and a case report with emphasis on radiological manifestation
by: Atoosa Adibi, et al.
Published: (2020-01-01)

Biliary tract cancers: current knowledge, clinical candidates and future challenges
by: Tariq N, et al.
Published: (2019-03-01)

Primary non-functioning neuroendocrine tumor of the extrahepatic bile duct
by: Santiago Sánchez-Cabús, et al.

Relevance of Preoperative Hyperbilirubinemia in Patients Undergoing Hepatobiliary Resection for Hilar Cholangiocarcinoma
by: Karolina Maria Wronka, et al.
Published: (2019-04-01)

Left hepatectomy for cholangiocarcinoma: case report and literature review
by: Antonio Luis de Vasconcelos Macedo, et al.
Published: (2003-03-01)

Efficacy and Safety of Pembrolizumab for Gemcitabine/Cisplatin-Refractory Biliary Tract Cancer: A Multicenter Retrospective Study
by: Sang Hoon Lee, et al.
Published: (2020-06-01)

Chemotherapy for Biliary Tract Cancer in 2021
by: Takashi Sasaki, et al.
Published: (2021-07-01)

Recent Progress in the Systemic Treatment of Advanced/Metastatic Cholangiocarcinoma
by: Raluca Maria Fostea, et al.
Published: (2020-09-01)

Paracellular/transcellular perturbations in hepatobiliary dysfuntion
by: Gilroy, Duncan J.
Published: (2013)

Extracellular Vesicles in Hepatobiliary Malignancies
by: Ainhoa Lapitz, et al.
Published: (2018-10-01)

Aspirin use is associated with a reduced risk of cholangiocarcinoma: a systematic review and meta-analysis
by: Xiong JP, et al.
Published: (2018-10-01)

PD-L1, TMB, MSI, and Other Predictors of Response toImmune Checkpoint Inhibitors in Biliary Tract Cancer
by: Alessandro Rizzo, et al.
Published: (2021-02-01)

Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions
by: Marc Hilmi, et al.
Published: (2019-11-01)

Integrative clinical and molecular analysis of advanced biliary tract cancers on immune checkpoint blockade reveals potential markers of response
by: Jingjing Li, et al.
Published: (2020-08-01)

Mass spectrometry-based analysis of formalin-fixed, paraffin-embedded distal cholangiocarcinoma identifies stromal thrombospondin-2 as a potential prognostic marker
by: Johannes Byrling, et al.
Published: (2020-09-01)

The Importance of Molecular Testing in the Treatment of Cholangiocarcinoma
by: David Malka, et al.
Published: (2020-11-01)

MicroRNAs in Hepatobiliary and Pancreatic Cancers
by: Yoshimasa eSaito, et al.
Published: (2011-09-01)

Recent Trends and In-Hospital Mortality of Transarterial Chemoembolization (TACE) in Germany: A Systematic Analysis of Hospital Discharge Data between 2010 and 2019
by: Essing, T., et al.
Published: (2022)

Plasma proteome plus site‐specific N‐glycoprofiling for hepatobiliary carcinomas
by: Ting‐Tsung Chang, et al.
Published: (2019-07-01)

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?
by: Angela Dalia Ricci, et al.
Published: (2020-08-01)

Efficacy and Safety of CAP7.1 as Second-Line Treatment for Advanced Biliary Tract Cancers: Data from a Randomised Phase II Study
by: Ulrich-Frank Pape, et al.
Published: (2020-10-01)

Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles
by: Eliza W. Beal, et al.
Published: (2021-12-01)

Cannot write session to /tmp/vufind_sessions/sess_1uh5k0frrpv81fbrmbc689dlq5